NICE endorses use of Roche's MabThera in rare autoimmune disorder

10/4/2013 | PharmaTimes (U.K.)

The U.K. National Institute for Health and Care Excellence published draft guidance endorsing the use of Roche's MabThera as a treatment for some adults with anti-neutrophil cytoplasmic antibody-associated vasculitis. The treatment is a cost-effective use of the National Health Service's resources if further cyclophosphamide treatment would go beyond the maximum cumulative dose, NICE concluded.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC